article thumbnail

Retail Community Pharmacist Wages Declined from 2012 to 2022

Drug Topics

Researchers addressed the wage gaps in specific pharmacy settings in relation to big chain retail pharmacy mergers.

143
143
article thumbnail

EC grants orphan drug designation for Precigen’s PRGN-2012

Pharmaceutical Technology

The EC has granted orphan drug designation (ODD) for Precigen's PRGN-2012 aimed at treating recurrent respiratory papillomatosis (RRP).

52
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

UK biotech sees worst funding downturn since 2012

pharmaphorum

Indeed, Initial Public Offerings (IPOs) raised just £28 million – the worst annual haul since 2012 – and, during the entirety of last year, UK biotech raised just £1.8 The post UK biotech sees worst funding downturn since 2012 appeared first on. billion, way down from £4.5 billion in 2021. billion raised.

article thumbnail

Diversity in clinical trials has actually dropped since 2012, IQVIA finds

Outsourcing Pharma

Despite diversity being spoken about more than ever before, research discovers clinical trials are less representative of the US population compared to a decade prior.

64
article thumbnail

Opinion: Why cancer advocates like me are leaving X

STAT

Since 2012, I’ve been blogging and on social media, connecting with the lung cancer community and learning/sharing developments in cancer research. I’ve been living with and communicating about lung cancer for over 13 years.

article thumbnail

340B program continues to drive shift in care to more expensive hospital settings

PhRMA

In this case, the Berkeley Research Group (BRG) found that nearly 36% of all Medicare Part B therapy sales occurred at 340B hospitals in 2021 , up nearly 17 percentage points since 2012, meaning care is moving from physician offices and non-340B hospitals to 340B hospitals.

Hospitals 286
article thumbnail

J&J's tuberculosis med Sirturo lands full US, EU approvals after more than a decade on the market

Fierce Pharma

The traditional approvals follow initial accelerated approvals granted by the FDA in 2012 and the European Commission in 2014. It took many years, but Johnson & Johnson’s tuberculosis med Sirturo can finally claim full approvals in the U.S. and Europe following initial conditional nods. |

FDA 110